Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QURE 
Uniqure NV (QURE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/16/2025: QURE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35.93
1 Year Target Price $35.93
| 9 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.45% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 789.47M USD | Price to earnings Ratio - | 1Y Target Price 35.93 |
Price to earnings Ratio - | 1Y Target Price 35.93 | ||
Volume (30-day avg) 13 | Beta 0.09 | 52 Weeks Range 4.45 - 19.18 | Updated Date 07/16/2025 |
52 Weeks Range 4.45 - 19.18 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-06-18 | When Before Market | Estimate -0.8863 | Actual -0.7278 |
Profitability
Profit Margin - | Operating Margin (TTM) -2815.25% |
Management Effectiveness
Return on Assets (TTM) -15.64% | Return on Equity (TTM) -241.16% |
Valuation
Trailing PE - | Forward PE 27.93 | Enterprise Value 421474004 | Price to Sales(TTM) 39.08 |
Enterprise Value 421474004 | Price to Sales(TTM) 39.08 | ||
Enterprise Value to Revenue 20.86 | Enterprise Value to EBITDA 0.99 | Shares Outstanding 54748500 | Shares Floating 35512064 |
Shares Outstanding 54748500 | Shares Floating 35512064 | ||
Percent Insiders 6.09 | Percent Institutions 91.95 |
Upturn AI SWOT
Uniqure NV
Company Overview
History and Background
uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, Netherlands. It is a pioneer in gene therapy, focusing on developing and commercializing transformative genetic medicines for patients with severe unmet medical needs. Initially focused on cardiovascular disease, the company shifted its focus to liver-directed gene therapies.
Core Business Areas
- Liver-Directed Gene Therapies: uniQure's primary focus is on developing gene therapies targeting the liver, where genetic modifications can have a significant impact on systemic diseases.
- Neurological Disorders: uniQure is also developing gene therapies for neurological disorders.
Leadership and Structure
uniQure is led by a management team with expertise in gene therapy and biotechnology. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Hemgenix (etranacogene dezaparvovec): Hemgenix is a gene therapy approved for the treatment of hemophilia B in adults. It is a one-time infusion designed to provide long-term factor IX expression, reducing the need for prophylactic treatment. CSL Behring is a competitor in this area.
- AMT-130: AMT-130 is an AAV5 gene therapy under investigation for the treatment of Huntington's disease. Currently in clinical trials, aiming to reduce the mutant Huntingtin protein, addressing the underlying genetic cause of the disease. WAVE Life Sciences and Roche are competitors in this area.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly evolving, with significant advancements in vector technology, gene editing, and delivery methods. The market is driven by the potential for curative therapies for genetic diseases.
Positioning
uniQure is a pioneer in gene therapy, focusing on liver-directed gene therapies and neurological disorders. Their competitive advantage lies in their experience, proprietary technology platforms, and clinical expertise.
Total Addressable Market (TAM)
The TAM for gene therapies is estimated to reach billions of dollars in the coming years. uniQure is well-positioned to capture a significant share of this market with its established pipeline and approved product.
Upturn SWOT Analysis
Strengths
- Pioneering gene therapy platform
- Approved product (Hemgenix)
- Strong pipeline of gene therapy candidates
- Experienced management team
- Proprietary AAV vector technology
Weaknesses
- High development costs
- Regulatory hurdles
- Manufacturing complexities
- Reliance on clinical trial success
- Commercialization challenges
Opportunities
- Expanding into new therapeutic areas
- Developing new gene therapy technologies
- Partnering with pharmaceutical companies
- Acquiring complementary technologies
- Expanding global reach
Threats
- Competition from other gene therapy companies
- Regulatory setbacks
- Manufacturing disruptions
- Clinical trial failures
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BMY
- VRTX
- CRSP
Competitive Landscape
uniQure faces competition from established pharmaceutical companies and other gene therapy developers. Its advantages include its proprietary technology and focus on liver-directed gene therapies.
Major Acquisitions
InoCell B.V.
- Year: 2013
- Acquisition Price (USD millions): 28.4
- Strategic Rationale: Enhanced manufacturing capabilities and process development expertise in cell-based therapies.
Growth Trajectory and Initiatives
Historical Growth: uniQure's historical growth has been driven by the advancement of its gene therapy pipeline and partnerships.
Future Projections: Future growth is projected to be driven by Hemgenix sales, clinical trial successes, and new product launches. Analyst estimates vary based on specific assumptions.
Recent Initiatives: Recent initiatives include advancing clinical trials for AMT-130 and other gene therapy candidates, as well as expanding manufacturing capacity.
Summary
uniQure is a pioneering gene therapy company with an approved product, Hemgenix. The high cost of gene therapy development and regulatory complexities are challenges. Success hinges on clinical trial outcomes and strategic partnerships. uniQure is positioned to capitalize on the growth of the gene therapy market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Uniqure NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2007-06-20 | CEO & Executive Director Mr. Matthew Craig Kapusta CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 209 | Website https://www.uniqure.com |
Full time employees 209 | Website https://www.uniqure.com | ||
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.